Chiara Gastaldon1,2, Emanuel Raschi3, John M Kane4,5,6, Corrado Barbui7, Georgios Schoretsanitis4. 1. WHO Collaborating Centre for Research and Training in Mental Health and Service Evaluation, Department of Neuroscience, Biomedicine and Movement Sciences, Section of Psychiatry, University of Verona, Verona, Italy, chiara.gastaldon@gmail.com. 2. The Zucker Hillside Hospital, Department of Psychiatry, Northwell Health, Glen Oaks, New York, USA, chiara.gastaldon@gmail.com. 3. Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy. 4. The Zucker Hillside Hospital, Department of Psychiatry, Northwell Health, Glen Oaks, New York, USA. 5. Department of Psychiatry and Molecular Medicine, Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, USA. 6. The Feinstein Institute for Medical Research, Center for Psychiatric Neuroscience, Manhasset, New York, USA. 7. WHO Collaborating Centre for Research and Training in Mental Health and Service Evaluation, Department of Neuroscience, Biomedicine and Movement Sciences, Section of Psychiatry, University of Verona, Verona, Italy.
Abstract
INTRODUCTION: Esketamine nasal spray received approval for treatment-resistant depression in March 2019. OBJECTIVE: Using the FDA Adverse Event Reporting System (FAERS) database (March 2019-March 2020), we analysed esketamine-related adverse events (AEs) to detect and characterize relevant safety signals. METHODS: We used the consolidated case/non-case approach to estimate the reporting odds ratio (ROR) and information component (IC) with relevant confidence intervals (95% CI) for esketamine-related AEs with ≥4 counts. Comparisons between serious and non-serious AEs were performed using non-parametric tests. RESULTS: The FAERS database contained 962 cases of esketamine-related AEs, with signals detected for several AEs, such as dissociation (ROR = 1,612.64, 95% CI = 1,354.63, 1,919.79; IC = 8.19, 95% CI = 7.96, 8.35), sedation (ROR = 238.46, 95% CI = 202.98, 280.15; IC = 7, 95% CI = 6.75, 7.18), feeling drunk (ROR = 96.17, 95% CI = 61.42, 150.57; IC = 4.84, 95% CI = 4.09, 5.36), suicidal ideation (ROR = 24.03, 95% CI = 18.72, 30.84; IC = 4.31, 95% CI = 3.9, 4.61), and completed suicide (ROR = 5.75, 95% CI = 3.18, 10.41; IC = 2.25, 95% CI = 1.23, 2.94). Signals for suicidal and self-injurious ideation, but not suicide attempt and completed suicide, remained when comparing esketamine to venlafaxine. Females and patients receiving antidepressant polypharmacy, co-medication with mood stabilizers, antipsychotics, benzodiazepines, or somatic medications were more likely to suffer from serious versus non-serious AEs (χ2 = 125.29, p < 0.001, χ2 = 9.08, p = 0.003, χ2 = 8.14, p = 0.004, χ2 = 19.48, p < 0.001, χ2 = 25.62, p < 0.001, and χ2 = 16.79, p < 0.001, respectively). CONCLUSIONS: Esketamine may carry a clear potential for serious AEs, which deserves urgent clarification by means of further prospective studies.
INTRODUCTION: Esketamine nasal spray received approval for treatment-resistant depression in March 2019. OBJECTIVE: Using the FDA Adverse Event Reporting System (FAERS) database (March 2019-March 2020), we analysed esketamine-related adverse events (AEs) to detect and characterize relevant safety signals. METHODS: We used the consolidated case/non-case approach to estimate the reporting odds ratio (ROR) and information component (IC) with relevant confidence intervals (95% CI) for esketamine-related AEs with ≥4 counts. Comparisons between serious and non-serious AEs were performed using non-parametric tests. RESULTS: The FAERS database contained 962 cases of esketamine-related AEs, with signals detected for several AEs, such as dissociation (ROR = 1,612.64, 95% CI = 1,354.63, 1,919.79; IC = 8.19, 95% CI = 7.96, 8.35), sedation (ROR = 238.46, 95% CI = 202.98, 280.15; IC = 7, 95% CI = 6.75, 7.18), feeling drunk (ROR = 96.17, 95% CI = 61.42, 150.57; IC = 4.84, 95% CI = 4.09, 5.36), suicidal ideation (ROR = 24.03, 95% CI = 18.72, 30.84; IC = 4.31, 95% CI = 3.9, 4.61), and completed suicide (ROR = 5.75, 95% CI = 3.18, 10.41; IC = 2.25, 95% CI = 1.23, 2.94). Signals for suicidal and self-injurious ideation, but not suicide attempt and completed suicide, remained when comparing esketamine to venlafaxine. Females and patients receiving antidepressant polypharmacy, co-medication with mood stabilizers, antipsychotics, benzodiazepines, or somatic medications were more likely to suffer from serious versus non-serious AEs (χ2 = 125.29, p < 0.001, χ2 = 9.08, p = 0.003, χ2 = 8.14, p = 0.004, χ2 = 19.48, p < 0.001, χ2 = 25.62, p < 0.001, and χ2 = 16.79, p < 0.001, respectively). CONCLUSIONS: Esketamine may carry a clear potential for serious AEs, which deserves urgent clarification by means of further prospective studies.
Authors: Adam Bayes; Brooke Short; Carlos A Zarate; Lawrence Park; James W Murrough; Declan M McLoughlin; Patricio Riva-Posse; Robert Schoevers; Jolien Veraart; Sagar Parikh; Paul Glue; Johnson Fam; Rupert McShane; Veronica Galvez; Donel Martin; Phern-Chern Tor; Andre R Brunoni; Colleen K Loo Journal: J Affect Disord Date: 2022-04-09 Impact factor: 6.533
Authors: T Taillefer de Laportalière; A Yrondi; A Jullien; P Cestac; F Montastruc Journal: Epidemiol Psychiatr Sci Date: 2022-01-11 Impact factor: 6.892
Authors: Felicia Ceban; Joshua D Rosenblat; Kevin Kratiuk; Yena Lee; Nelson B Rodrigues; Hartej Gill; Mehala Subramaniapillai; Flora Nasri; Leanna M W Lui; Orly Lipsitz; Anil Kumar; Jung Goo Lee; Edmond H Chau; Bing Cao; Kangguang Lin; Roger C Ho; Rodrigo B Mansur; Jennifer Swainson; Roger S McIntyre Journal: CNS Drugs Date: 2021-08-07 Impact factor: 5.749
Authors: Zhengchao Dong; Michael F Grunebaum; Martin J Lan; Vashti Wagner; Tse-Hwei Choo; Matthew S Milak; Tarek Sobeih; J John Mann; Joshua T Kantrowitz Journal: Front Psychiatry Date: 2021-06-02 Impact factor: 4.157
Authors: Joshua T Kantrowitz; Zhengchao Dong; Matthew S Milak; Rain Rashid; Lawrence S Kegeles; Daniel C Javitt; Jeffrey A Lieberman; J John Mann Journal: Transl Psychiatry Date: 2021-08-05 Impact factor: 6.222